Progyny, INC 10-Q quarterly reports

Progyny, Inc. announced its Q2 2026 results, showcasing a 5% increase in revenue driven by its fertility and pharmacy benefits solutions, alongside a notable improvement in gross margin.

Progyny, Inc. reports a significant 61% increase in net income for Q1 2026, driven by client expansion and improved gross margin, despite a modest 1% revenue growth.

Progyny, Inc. reported strong third-quarter 2025 financial results with a 9% revenue increase and a 33% rise in net income, driven by growth in fertility benefits and Progyny Rx solutions.

Progyny, Inc. reports strong revenue growth and improved gross margins in Q2 2025, driven by increased client adoption and utilization of its fertility and pharmacy benefits solutions.

Progyny's Q1 2025 results show a 17% increase in revenue, driven by growth in both fertility benefits and pharmacy solutions, alongside an expanding client base.

Progyny's Q3 2024 results show a slight revenue increase but a decrease in net income compared to the same period last year, alongside a significant share repurchase program.

Progyny, Inc. announced its second quarter 2024 financial results, showing a 9% increase in revenue compared to the same period last year, driven by growth in both fertility and pharmacy benefits solutions.

Progyny's first quarter of 2024 shows revenue growth driven by increased client base and utilization, alongside strategic investments in share repurchases and new executive severance plan.